Targets › AURKB
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Feb 2027.
Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. (UniProt, Q96GD4)
Open in Phaseline: the race on AURKB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chipscreen Biosciences | Ibcasertib Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor | AURKB, FLT1, FLT4, KDR | Phase 2 | Pancreatic Ductal Adenocarcinoma | Feb 2027 |
Pancreatic Ductal Adenocarcinoma (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.